This video features two presentations on advancements in digital PCR (dPCR) applications for genetic analysis. The first segment details a dPCR-based method for DNA methylation analysis, proposing a methylation-sensitive restriction enzyme approach as a superior alternative to bisulfite treatment for UNG PCR systems. It addresses the challenge of high GC content in CpG regions by optimizing high GC enhancers, demonstrating the utility of the Roche Digital Light Cycler (DLC) for accurate quantification and methylation fraction calculation in RASSF1A promoter studies. The second presentation, by Stephanie Barbery from GT Molecular, introduces a multiplexed dPCR panel designed for Acute Myeloid Leukemia (AML) on the Roche DLC. This panel targets critical mutations in IDH1, IDH2, and NPM1, highlighting their importance for minimal residual disease (MRD) monitoring via liquid biopsy. The benefits of liquid biopsy for non-invasive, longitudinal monitoring and the high sensitivity of dPCR for detecting rare mutant alleles are emphasized. Real-world patient data from liver and pancreatic cancers validate the panel's effectiveness in detecting IDH mutations from plasma cell-free DNA, demonstrating its potential for tracking disease progression and treatment response. GT Molecular also announces forthcoming oncology dPCR assays for other cancer types.
Summary:
0:00 Introduction to DNA Methylation: DNA methylation is a crucial epigenetic modification involved in gene expression, tissue differentiation, and various diseases, including cancer.
0:45 Bisulfite Treatment Limitations: The common bisulfite treatment for methylation analysis is incompatible with UNG PCR systems (used for carryover contamination prevention) because it converts unmethylated cytosine to uracil, which UNG digests.
2:02 Alternative dPCR-Based Method: An alternative approach using methylation-sensitive restriction enzymes (which selectively digest unmethylated CpGs) followed by digital PCR (dPCR) is proposed.
2:53 Digital PCR Advantages: dPCR enables absolute quantification without relying on standards, offers enhanced precision through sample partitioning, increases sensitivity, reduces competition, and shows better tolerance to inhibitors.
4:52 Roche Digital Light Cycler (DLC) Features: The Roche DLC system provides a flexible workflow with a 5x concentrated master mix, three types of nanowell plates (high sensitivity, universal, high resolution with up to 100,000 partitions), and six optical channels for multiplexing. It consistently yields a high number of valid partitions.
8:06 Overcoming GC Bias: Initial analysis of the RASSF1A promoter showed low quantification due to high GC content. This was significantly improved by adding high GC enhancers (e.g., DMSO, Glycal) to the PCR reaction, boosting accuracy to within 95% confidence intervals.
10:41 Methylation Detection and Calculation: A multiplex dPCR assay utilizing the HhaI restriction enzyme and reference genes (for digestion completion and input correction) effectively distinguished methylated from unmethylated DNA. A method for calculating methylation fraction based on the ratio of target to reference gene before and after digestion was demonstrated.
14:04 Cancer Cell Line Analysis: The method was applied to various cancer cell lines, revealing a broad range of RASSF1A methylation levels (e.g., 7% in promoter, <0.1% in exon 1) compared to healthy human genomic DNA.
15:40 GT Molecular's AML Panel: Stephanie Barbery from GT Molecular introduced a dPCR panel for Acute Myeloid Leukemia (AML), developed for the Roche DLC, specifically for minimal residual disease (MRD) monitoring.
17:23 Liquid Biopsy for Cancer Care: Liquid biopsies are highlighted as an ideal, non-invasive method for longitudinal cancer monitoring, capable of capturing tumor heterogeneity and detecting MRD.
19:30 dPCR's Role in MRD: dPCR is considered the most sensitive method for MRD detection, critical for identifying rare mutant DNA molecules among abundant wild-type DNA in liquid biopsy samples.
20:15 AML Panel Targets: The AML panel targets key mutations in NPM1 (common insertions, positive prognostic risk, early marker) and IDH1/IDH2 (common hotspot mutations, early markers, and targets for therapy).
26:27 NPM1 Drop-off Assay: The NPM1 assay uses a unique "drop-off" approach where an insertion event at the target site leads to a loss of signal for one probe, allowing for clear distinction of mutant populations in 2D analysis.
28:19 IDH Assays Performance: The IDH1 R132H, IDH2 R140Q, and R172K assays demonstrated robust signal-to-noise ratios, no cross-reactivity, and effective detection of low variant allele frequencies (VAFs).
28:59 High Sensitivity and Broad Compatibility: The panel achieves a limit of detection of at least 0.3% VAF and is compatible with DNA from various matrices, including plasma, whole blood, FFPE, and bone marrow.
29:48 Real-World Sample Validation: The panel successfully detected IDH mutations in cell-free DNA from plasma samples of liver and pancreatic cancer patients, showing its potential for monitoring disease progression and treatment response.
31:26 Future Oncology Assays: GT Molecular plans to release additional oncology dPCR assays for the Roche DLC, including BCR-ABL fusions for Chronic Myeloid Leukemia (CML) and an ESR1 inhibitor resistant mutation panel for breast cancer.